A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

10.1038/s41408-021-00544-x

Saved in:

Bibliographic Details
Main Authors:	Chen, Yunxin, Gopalakrishnan, Sathish Kumar, Ooi, Melissa, Sultana, Rehena, Lim, Li Hui, Grigoropoulos, Nicholas, Ong, Shin Yeu, Xu, Mingge, Chng, Wee Joo, Goh, Yeow Tee, Nagarajan, Chandramouli
Other Authors:	CANCER SCIENCE INSTITUTE OF SINGAPORE
Format:	Letter
Language:	English
Published:	SPRINGERNATURE 2021
Subjects:	Science & Technology Life Sciences & Biomedicine Oncology Hematology MULTIPLE-MYELOMA LENALIDOMIDE
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/207736
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

id	sg-nus-scholar.10635-207736
record_format	dspace
spelling	sg-nus-scholar.10635-2077362024-04-17T09:55:50Z A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1) Chen, Yunxin Gopalakrishnan, Sathish Kumar Ooi, Melissa Sultana, Rehena Lim, Li Hui Grigoropoulos, Nicholas Ong, Shin Yeu Xu, Mingge Chng, Wee Joo Goh, Yeow Tee Nagarajan, Chandramouli CANCER SCIENCE INSTITUTE OF SINGAPORE DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL) MEDICINE DUKE-NUS MEDICAL SCHOOL Science & Technology Life Sciences & Biomedicine Oncology Hematology MULTIPLE-MYELOMA LENALIDOMIDE 10.1038/s41408-021-00544-x BLOOD CANCER JOURNAL 11 9 2021-11-24T03:21:08Z 2021-11-24T03:21:08Z 2021-09-03 2021-11-22T06:17:44Z Letter Chen, Yunxin, Gopalakrishnan, Sathish Kumar, Ooi, Melissa, Sultana, Rehena, Lim, Li Hui, Grigoropoulos, Nicholas, Ong, Shin Yeu, Xu, Mingge, Chng, Wee Joo, Goh, Yeow Tee, Nagarajan, Chandramouli (2021-09-03). A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). BLOOD CANCER JOURNAL 11 (9). ScholarBank@NUS Repository. https://doi.org/10.1038/s41408-021-00544-x 20445385 2044-5385 https://scholarbank.nus.edu.sg/handle/10635/207736 en SPRINGERNATURE Elements
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
language	English
topic	Science & Technology Life Sciences & Biomedicine Oncology Hematology MULTIPLE-MYELOMA LENALIDOMIDE
spellingShingle	Science & Technology Life Sciences & Biomedicine Oncology Hematology MULTIPLE-MYELOMA LENALIDOMIDE Chen, Yunxin Gopalakrishnan, Sathish Kumar Ooi, Melissa Sultana, Rehena Lim, Li Hui Grigoropoulos, Nicholas Ong, Shin Yeu Xu, Mingge Chng, Wee Joo Goh, Yeow Tee Nagarajan, Chandramouli A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)
description	10.1038/s41408-021-00544-x
author2	CANCER SCIENCE INSTITUTE OF SINGAPORE
author_facet	CANCER SCIENCE INSTITUTE OF SINGAPORE Chen, Yunxin Gopalakrishnan, Sathish Kumar Ooi, Melissa Sultana, Rehena Lim, Li Hui Grigoropoulos, Nicholas Ong, Shin Yeu Xu, Mingge Chng, Wee Joo Goh, Yeow Tee Nagarajan, Chandramouli
format	Letter
author	Chen, Yunxin Gopalakrishnan, Sathish Kumar Ooi, Melissa Sultana, Rehena Lim, Li Hui Grigoropoulos, Nicholas Ong, Shin Yeu Xu, Mingge Chng, Wee Joo Goh, Yeow Tee Nagarajan, Chandramouli
author_sort	Chen, Yunxin
title	A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)
title_short	A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)
title_full	A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)
title_fullStr	A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)
title_full_unstemmed	A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)
title_sort	phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible mm with high-risk features (sgh-mm1)
publisher	SPRINGERNATURE
publishDate	2021
url	https://scholarbank.nus.edu.sg/handle/10635/207736
_version_	1800915143720173568

A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

Similar Items